Table 4

Recommendations on use of antibiotics and immunoglobulins

GuidelineCountryYearAntibioticsIndicationsImmunoglobulinsIndications
China (MoH)54China2003RSecondary bacterial infections.NS
Dermatology Advisor47Global2017NSVIGConsider in severe infection.
DermNet48Global2014NSNS
ECDC56Europe2019NSNS
eMedicine49Global2020NSNSNotes that VIG has not shown efficacy for treatment.
Ireland HPSC53Ireland2021NSNS
Medscape51Global2019NSNSNotes that VIG has not shown efficacy in treatment.
NCDC44Nigeria2019RSecondary bacterial infections
cefuroxime 500 mg two times, 5 days (oral/parental) or
ceftriaxone intravenous 1 g, 5 days or
B-lactam antibiotics (amoxyl/clavulanic acid, 625 mg ×2/day, ≥5 days.
NS
PHE/UKHSA52England2019NSNS
Singapore FETP46Singapore2020NSNS
Taiwan CDC45Taiwan2009NSNS
UpToDate50Global2021NSNS
US CDC55USA2018NSVIGCan be considered in severe cases.
WHO18Global2019NSNS
  • CDC, Centers for Disease Control; ECDC, European Centre for Disease Control and Prevention; FETP, Singapore Field Epidemiology Training Programme; HPSC, Health Protection Surveillance Centre; MoH, Ministry of Health; NA, not applicable; NCDC, Nigeria Centre for Disease Control; PHE, Public Health England; UKHSA, UK Health Security Agency; VIG, vaccinia immune globulin.